📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Marksans Pharma Q3 FY26 Revenue Hits Record INR 754 Cr; EBITDA Margins Expand to 21.3%
Marksans Pharma reported a resilient Q3 FY26 with record operating revenue of INR 754.4 crores, a 10.6% YoY increase driven by strong US performance and seasonal demand. EBITDA margins expanded significantly by 217 bps to 21.3% due to operating leverage and softening raw material costs. The company remains debt-free with a robust cash balance of INR 824.2 crores and a strong US order book exceeding $220 million. Management is actively pursuing global expansion through new subsidiaries in Europe and Canada while targeting a long-term revenue milestone of INR 4,000 crores.
Key Highlights
Q3 FY26 revenue grew 10.6% YoY to an all-time high of INR 754.4 crores.
EBITDA increased 23.2% YoY to INR 160.7 crores with margins expanding to 21.3%.
US and North American markets grew 16.9% YoY, supported by a $220 million+ order book.
The company remains debt-free with a cash surplus of INR 824.2 crores as of December 2025.
Teva facility utilization is improving, currently contributing INR 560-600 crores toward an INR 800 crore target.
💼 Action for Investors
Investors should view the margin expansion and strong US order book as positive indicators of operational efficiency. The company's debt-free status and significant cash reserves provide a strong cushion for its planned M&A and international expansion.
Marksans Pharma Q3 FY26: Revenue Up 10.6% YoY to ₹754.4 Cr, EBITDA Margin Hits 21.3%
Marksans Pharma reported a resilient Q3 FY26 with operating revenue growing 10.6% YoY to ₹754.4 crore, driven by strong volume growth in the US and Australia markets. EBITDA grew significantly by 23.2% YoY to ₹160.7 crore, with margins expanding by 217 bps to 21.3% due to favorable raw material costs and currency tailwinds. While quarterly PAT rose 8.2% YoY to ₹113.7 crore, the nine-month PAT remains down 7.1% YoY at ₹271.0 crore. The company maintains a robust cash balance of ₹824.2 crore and is expanding its global footprint with new subsidiaries in Europe and Canada.
Key Highlights
Operating revenue increased 10.6% YoY to ₹754.4 cr, with US market revenue growing 16.9% to ₹412.4 cr.
EBITDA rose 23.2% YoY to ₹160.7 cr, with EBITDA margins expanding 217 bps YoY to 21.3%.
Quarterly PAT grew 8.2% YoY to ₹113.7 cr, though 9MFY26 PAT is down 7.1% YoY at ₹271.0 cr.
Strong cash position of ₹824.2 cr as of December 31, 2025, with ₹263.2 cr cash generated from operations in 9MFY26.
Australia and New Zealand business reported robust growth of 30.1% YoY, reaching ₹61.4 cr.
💼 Action for Investors
Investors should monitor the sustainability of the 21% EBITDA margins and the progress of the new European and Canadian subsidiaries. The strong cash position and recovery in quarterly PAT suggest a positive trend despite a weaker 9-month performance.
Marksans Pharma Q3 FY26: Revenue Up 10.6% to ₹754 Cr, EBITDA Margins Expand to 21.3%
Marksans Pharma reported a resilient Q3 FY26 performance with operating revenue growing 10.6% YoY to ₹754.4 crore. EBITDA saw a significant jump of 23.2% YoY to ₹160.7 crore, with margins expanding to 21.3% due to soft raw material costs and favorable currency movements. The US market led growth with a 16.9% YoY increase, while the company maintained a strong cash position of ₹824.2 crore. Despite a soft Q1, the 9M FY26 trajectory shows recovery with profitability improving meaningfully in the recent quarters.
Key Highlights
Q3 FY26 Revenue grew 10.6% YoY to ₹754.4 cr and PAT rose 8.2% YoY to ₹113.7 cr
EBITDA margins expanded 220 bps YoY to 21.3%, driven by operating leverage and product mix
US & North America revenue reached ₹412.4 cr, up 16.9% YoY, aided by winter seasonality
Cash balance remains strong at ₹824.2 cr with 9M FY26 operating cash flow of ₹263.2 cr
R&D investment for 9M FY26 stood at ₹62.0 cr, representing 3.0% of consolidated revenue
💼 Action for Investors
The stock remains a positive play on the OTC segment growth in regulated markets like the US and UK. Investors should monitor the integration of the new Goa facility which is expected to double capacity and drive future volume growth.
Marksans Pharma Q3 PAT Surges 192% YoY to ₹609.11 Million; Revenue Up 38%
Marksans Pharma reported a stellar performance for Q3 FY26, with consolidated revenue from operations growing 38.3% YoY to ₹3,597.20 million. Net profit (PAT) witnessed a massive jump of 192% YoY, reaching ₹609.11 million compared to ₹208.41 million in the same period last year. The company is actively pursuing global expansion, having incorporated new subsidiaries in Ireland and Canada in January 2026. Despite a one-time impact of ₹28.10 million from new labour code provisions, the company's operational efficiency remains high with an EPS of ₹1.34.
Key Highlights
Revenue from operations grew 38.3% YoY to ₹3,597.20 million in Q3 FY26.
Net Profit (PAT) increased significantly to ₹609.11 million from ₹208.41 million in the year-ago period.
Earnings Per Share (EPS) rose to ₹1.34 for the quarter, up from ₹0.46 in Q3 FY25.
Incorporated two new wholly-owned subsidiaries in Ireland and Canada in January 2026 to drive international expansion.
Accounted for a ₹28.10 million incremental impact due to the implementation of New Labour Codes.
💼 Action for Investors
Investors should take note of the strong triple-digit profit growth and aggressive international expansion. The stock remains a positive prospect for long-term investors given the consistent improvement in margins and global footprint.
Marksans Pharma Incorporates Two New Wholly Owned Subsidiaries in Ireland and Canada
Marksans Pharma Limited has expanded its global footprint by incorporating two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. Both entities are established to carry out the business of pharmaceutical products in their respective regions. While these are newly formed entities with no immediate turnover, they represent a strategic move to strengthen the company's direct presence in the European and North American markets. This expansion aligns with the company's long-term growth strategy to scale its international operations.
Key Highlights
Incorporation of Marksans Pharma (Europe) Limited as a 100% subsidiary in Ireland.
Incorporation of Marksans (Canada) Inc. as a 100% subsidiary in Canada.
Both subsidiaries are dedicated to the pharmaceutical products business segment.
The entities are newly incorporated with no prior history of turnover or size.
Move aimed at enhancing market penetration in the European and Canadian pharmaceutical sectors.
💼 Action for Investors
Investors should monitor these developments as they indicate the company's intent to scale international operations. No immediate action is required, but look for future revenue contributions from these regions in upcoming fiscal years.